Comparative Pharmacology
Head-to-head clinical analysis: OXYBUTYNIN CHLORIDE versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYBUTYNIN CHLORIDE versus PATHILON.
OXYBUTYNIN CHLORIDE vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxybutynin chloride is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), leading to relaxation of the detrusor muscle and reduction of urinary bladder contractions.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (100 mg) applied once daily.
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 12–13 hours in plasma; clinical effect may persist longer due to active metabolite (N-desethyloxybutynin, half-life ~12–13 hours).
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Primarily hepatic metabolism; <0.1% excreted unchanged in urine. Metabolites (e.g., N-desethyloxybutynin) excreted mainly renally. Fecal elimination <0.02%.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category A/B
Category C
Anticholinergic
Anticholinergic